Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.17
ACET's Cash-to-Debt is ranked lower than
88% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. ACET: 0.17 )
Ranked among companies with meaningful Cash-to-Debt only.
ACET' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 4.28 Max: N/A
Current: 0.17
Equity-to-Asset 0.38
ACET's Equity-to-Asset is ranked lower than
80% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. ACET: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
ACET' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38  Med: 0.67 Max: 0.77
Current: 0.38
0.38
0.77
Interest Coverage 2.83
ACET's Interest Coverage is ranked lower than
84% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. ACET: 2.83 )
Ranked among companies with meaningful Interest Coverage only.
ACET' s Interest Coverage Range Over the Past 10 Years
Min: 2.83  Med: 18.65 Max: 147.43
Current: 2.83
2.83
147.43
Piotroski F-Score: 3
Altman Z-Score: 1.60
Beneish M-Score: -2.07
WACC vs ROIC
8.07%
4.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 6.10
ACET's Operating Margin % is ranked lower than
54% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. ACET: 6.10 )
Ranked among companies with meaningful Operating Margin % only.
ACET' s Operating Margin % Range Over the Past 10 Years
Min: 2.72  Med: 5.83 Max: 10.39
Current: 6.1
2.72
10.39
Net Margin % 2.79
ACET's Net Margin % is ranked lower than
60% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. ACET: 2.79 )
Ranked among companies with meaningful Net Margin % only.
ACET' s Net Margin % Range Over the Past 10 Years
Min: 1.9  Med: 3.79 Max: 6.22
Current: 2.79
1.9
6.22
ROE % 4.73
ACET's ROE % is ranked lower than
51% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ACET: 4.73 )
Ranked among companies with meaningful ROE % only.
ACET' s ROE % Range Over the Past 10 Years
Min: 4.68  Med: 10.25 Max: 13.73
Current: 4.73
4.68
13.73
ROA % 2.17
ACET's ROA % is ranked lower than
51% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. ACET: 2.17 )
Ranked among companies with meaningful ROA % only.
ACET' s ROA % Range Over the Past 10 Years
Min: 2.17  Med: 6.16 Max: 7.33
Current: 2.17
2.17
7.33
ROC (Joel Greenblatt) % 18.37
ACET's ROC (Joel Greenblatt) % is ranked higher than
62% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. ACET: 18.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ACET' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 12.2  Med: 25.97 Max: 38.21
Current: 18.37
12.2
38.21
3-Year Revenue Growth Rate 1.20
ACET's 3-Year Revenue Growth Rate is ranked lower than
67% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. ACET: 1.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ACET' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 6 Max: 14.9
Current: 1.2
0.9
14.9
3-Year EBITDA Growth Rate 16.10
ACET's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. ACET: 16.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ACET' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.6  Med: 6.8 Max: 44.7
Current: 16.1
-19.6
44.7
3-Year EPS without NRI Growth Rate 13.40
ACET's 3-Year EPS without NRI Growth Rate is ranked higher than
61% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. ACET: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ACET' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -25.9  Med: 7.3 Max: 59.8
Current: 13.4
-25.9
59.8
GuruFocus has detected 4 Warning Signs with Aceto Corp $ACET.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ACET's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ACET Guru Trades in Q2 2016

Keeley Asset Management Corp 47,700 sh (New)
Chuck Royce 1,215,573 sh (+187.24%)
Paul Tudor Jones Sold Out
Ken Fisher 167,853 sh (-9.50%)
Jim Simons 20,100 sh (-75.87%)
» More
Q3 2016

ACET Guru Trades in Q3 2016

Chuck Royce 2,522,555 sh (+107.52%)
Keeley Asset Management Corp 71,750 sh (+50.42%)
Jim Simons Sold Out
Ken Fisher 122,091 sh (-27.26%)
» More
Q4 2016

ACET Guru Trades in Q4 2016

Paul Tudor Jones 15,200 sh (New)
Keeley Asset Management Corp 71,050 sh (-0.98%)
Chuck Royce 1,743,186 sh (-30.90%)
Ken Fisher 70,105 sh (-42.58%)
» More
Q1 2017

ACET Guru Trades in Q1 2017

Ken Fisher 103,850 sh (+48.13%)
Paul Tudor Jones Sold Out
Chuck Royce 146,600 sh (-91.59%)
» More
» Details

Insider Trades

Latest Guru Trades with ACET

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:TLGT, NAS:KPTI, NAS:SCLN, NAS:SCMP, NAS:LBIO, NAS:AQXP, NAS:ADMS, NAS:RIGL, NAS:FLXN, NAS:TOCA, OTCPK:APHQF, NAS:TTPH, NAS:SNDX, NAS:COLL, NAS:ZYNE, NAS:DEPO, OTCPK:ACBFF, OTCPK:OGRMF, NAS:NEOS, NAS:STDY » details
Traded in other countries:AZJ.Germany,
Headquarter Location:USA
Aceto Corp is engaged in the marketing, sells and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, and specialty performance chemicals.

Aceto Corp is engaged in the marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals. Its operations are organized into three segments - Human Health, Pharmaceutical Ingredients and Performance Chemicals. The Human Health segment supply's raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds, and bio chemicals used in pharmaceutical and nutritional preparations. This segment markets and distributes its generic prescription and over the counter pharmaceutical products to wholesalers; chain drug stores; distributors; mass market merchandisers; and others. The Pharmaceutical Ingredients segment offers active pharmaceutical ingredients and pharmaceutical intermediates to various generic drug companies. The Performance Chemicals segment provides specialty chemicals, such as antioxidants, photo initiators, catalysts, curatives, brighteners, and adhesion promoters, which make plastics, surface coatings, textiles, fuels, and lubricants; diazos and couplers used in microfilms and blueprints, as well as in the photo tooling of printed circuit boards; and organic intermediates and colorants. Its raw materials are also used in electronic parts and binders. This segment also offers agricultural protection products comprising herbicides, fungicides, and insecticides, which control weed growth and the spread of insects and microorganisms; and sprout inhibitor for potatoes. The Company serves various companies, including small trading and fortune 500 companies in the industrial chemical, agricultural, and human health and pharmaceutical market.

Top Ranked Articles about Aceto Corp

ACETO Board of Directors Declares Quarterly Cash Dividend 
ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference Call
ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg

PORT WASHINGTON, N.Y., March 28, 2017 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150 & 500 mg, an AB-rated generic version of Xeloda® Tablets from Hoffman La Roche.  Capecitabine Tablets, 150 & 500 mg, which are indicated for the treatment of metastatic breast cancer, had U.S. sales of approximately $393 million for the 12 months ending December 2016, according to IMS Health.
ACETO Corporation sells generic prescription products and over-the-counter pharmaceutical products under its Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, and the launch of Capecitabine Tablets adds to its significant human pharmaceutical franchise.  Rising Pharmaceuticals has built a commercial portfolio of over 110 products currently in the U.S. market. It also has a development portfolio of more than 80 ANDAs filed with the FDA or pending launch, representing over $10 billion in addressable market value, using recent IMS sales data.   ABOUT ACETO ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products). FORWARD LOOKING STATEMENTS This news release contains forward-looking statements as that term is defined in the federal securities laws.  The events described in forward-looking statements contained in this news release may not occur.  Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO’s plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make, or a projection involving anticipated revenues, earnings or other aspects of ACETO’s operating results or financial position, and the outcome of any contingencies.  Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company’s strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth.   ACETO cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond ACETO’s control, which may influence the accuracy of the statements and the projections upon which the statements are based.  Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO’s reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016 and other filings. Copies of these filings are available at www.sec.gov.  Any one or more of these uncertainties, risks and other influences could materially affect ACETO’s results of operations and whether forward-looking statements made by ACETO ultimately prove to be accurate. In addition, periodic high-margin product sales may have a positive material financial impact in a given quarter that may be non-recurring in future quarters, thereby rendering one quarter's performance not useful as a predictor of future quarters' results.  ACETO’s actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements.  ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
Investor Relations Contact:
LHA
Jody Burfening
[email protected]
(212) 838-3777

Read more...

Ratios

vs
industry
vs
history
PE Ratio 28.33
ACET's PE Ratio is ranked higher than
65% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. ACET: 28.33 )
Ranked among companies with meaningful PE Ratio only.
ACET' s PE Ratio Range Over the Past 10 Years
Min: 8.5  Med: 19.9 Max: 91.83
Current: 28.33
8.5
91.83
Forward PE Ratio 7.47
ACET's Forward PE Ratio is ranked higher than
85% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. ACET: 7.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.33
ACET's PE Ratio without NRI is ranked higher than
65% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. ACET: 28.33 )
Ranked among companies with meaningful PE Ratio without NRI only.
ACET' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.5  Med: 19.9 Max: 91.83
Current: 28.33
8.5
91.83
Price-to-Owner-Earnings 18.23
ACET's Price-to-Owner-Earnings is ranked higher than
66% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. ACET: 18.23 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ACET' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.52  Med: 22.66 Max: 178.65
Current: 18.23
7.52
178.65
PB Ratio 1.28
ACET's PB Ratio is ranked higher than
84% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. ACET: 1.28 )
Ranked among companies with meaningful PB Ratio only.
ACET' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.54 Max: 3.37
Current: 1.28
0.83
3.37
PS Ratio 0.84
ACET's PS Ratio is ranked higher than
86% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. ACET: 0.84 )
Ranked among companies with meaningful PS Ratio only.
ACET' s PS Ratio Range Over the Past 10 Years
Min: 0.31  Med: 0.61 Max: 1.62
Current: 0.84
0.31
1.62
Price-to-Free-Cash-Flow 11.07
ACET's Price-to-Free-Cash-Flow is ranked higher than
68% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. ACET: 11.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ACET' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.68  Med: 20.38 Max: 543
Current: 11.07
7.68
543
Price-to-Operating-Cash-Flow 9.84
ACET's Price-to-Operating-Cash-Flow is ranked higher than
63% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. ACET: 9.84 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ACET' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.09  Med: 16.29 Max: 217.3
Current: 9.84
6.09
217.3
EV-to-EBIT 20.23
ACET's EV-to-EBIT is ranked higher than
55% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. ACET: 20.23 )
Ranked among companies with meaningful EV-to-EBIT only.
ACET' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.2  Med: 11.2 Max: 45.7
Current: 20.23
4.2
45.7
EV-to-EBITDA 13.47
ACET's EV-to-EBITDA is ranked higher than
55% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. ACET: 13.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
ACET' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 9.4 Max: 22.2
Current: 13.47
4
22.2
PEG Ratio 1.24
ACET's PEG Ratio is ranked higher than
74% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. ACET: 1.24 )
Ranked among companies with meaningful PEG Ratio only.
ACET' s PEG Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.17 Max: 18.99
Current: 1.24
0.35
18.99
Shiller PE Ratio 20.68
ACET's Shiller PE Ratio is ranked higher than
79% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. ACET: 20.68 )
Ranked among companies with meaningful Shiller PE Ratio only.
ACET' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 21.37 Max: 47.52
Current: 20.68
11.39
47.52
Current Ratio 2.07
ACET's Current Ratio is ranked lower than
56% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. ACET: 2.07 )
Ranked among companies with meaningful Current Ratio only.
ACET' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 3.15 Max: 4.33
Current: 2.07
2.07
4.33
Quick Ratio 1.47
ACET's Quick Ratio is ranked lower than
60% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. ACET: 1.47 )
Ranked among companies with meaningful Quick Ratio only.
ACET' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.97 Max: 2.94
Current: 1.47
1.21
2.94
Days Inventory 97.22
ACET's Days Inventory is ranked higher than
60% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. ACET: 97.22 )
Ranked among companies with meaningful Days Inventory only.
ACET' s Days Inventory Range Over the Past 10 Years
Min: 76.06  Med: 81.97 Max: 97.22
Current: 97.22
76.06
97.22
Days Sales Outstanding 164.20
ACET's Days Sales Outstanding is ranked lower than
84% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. ACET: 164.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACET' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.39  Med: 74.13 Max: 164.2
Current: 164.2
61.39
164.2
Days Payable 92.15
ACET's Days Payable is ranked higher than
57% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. ACET: 92.15 )
Ranked among companies with meaningful Days Payable only.
ACET' s Days Payable Range Over the Past 10 Years
Min: 34.34  Med: 45.41 Max: 92.15
Current: 92.15
34.34
92.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.74
ACET's Dividend Yield % is ranked higher than
52% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. ACET: 1.74 )
Ranked among companies with meaningful Dividend Yield % only.
ACET' s Dividend Yield % Range Over the Past 10 Years
Min: 0.79  Med: 2.1 Max: 4.01
Current: 1.74
0.79
4.01
Dividend Payout Ratio 0.48
ACET's Dividend Payout Ratio is ranked higher than
51% of the 410 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. ACET: 0.48 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ACET' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.34 Max: 0.77
Current: 0.48
0.2
0.77
3-Year Dividend Growth Rate 2.90
ACET's 3-Year Dividend Growth Rate is ranked lower than
64% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. ACET: 2.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
ACET' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -43  Med: 7 Max: 192.4
Current: 2.9
-43
192.4
Forward Dividend Yield % 1.80
ACET's Forward Dividend Yield % is ranked higher than
52% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. ACET: 1.80 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.21
ACET's 5-Year Yield-on-Cost % is ranked lower than
51% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. ACET: 2.21 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ACET' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.98  Med: 2.62 Max: 5
Current: 2.21
0.98
5
3-Year Average Share Buyback Ratio -2.10
ACET's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. ACET: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACET' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.4  Med: -0.6 Max: 6.2
Current: -2.1
-4.4
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.98
ACET's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. ACET: 0.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ACET' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.02 Max: 2.95
Current: 0.98
0
2.95
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.50
ACET's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
56% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.33 vs. ACET: 1.50 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.31
ACET's Price-to-Median-PS-Value is ranked lower than
68% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ACET: 1.31 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACET' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.81 Max: 2.4
Current: 1.31
0
2.4
Price-to-Peter-Lynch-Fair-Value 2.23
ACET's Price-to-Peter-Lynch-Fair-Value is ranked higher than
55% of the 174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. ACET: 2.23 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ACET' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.18 Max: 6.02
Current: 2.23
0
6.02
Earnings Yield (Greenblatt) % 4.97
ACET's Earnings Yield (Greenblatt) % is ranked higher than
68% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. ACET: 4.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACET' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 8.9 Max: 23.6
Current: 4.97
2.2
23.6
Forward Rate of Return (Yacktman) % 17.65
ACET's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.72 vs. ACET: 17.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ACET' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 12.3 Max: 48.8
Current: 17.65
-1.4
48.8

More Statistics

Revenue (TTM) (Mil) $579.1
EPS (TTM) $ 0.52
Beta1.16
Short Percentage of Float10.04%
52-Week Range $13.50 - 25.98
Shares Outstanding (Mil)30.10

Analyst Estimate

Jun17 Jun18
Revenue (Mil $) 644 760
EPS ($) 1.48 1.94
EPS without NRI ($) 1.48 1.94
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.00%
Dividends per Share ($)
» More Articles for ACET

Headlines

Articles On GuruFocus.com
ACETO Board of Directors Declares Quarterly Cash Dividend  May 04 2017 
ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference Apr 21 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg Mar 31 2017 
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg Mar 28 2017 
9 Cheap High-Yield Stocks Feb 23 2017 
5 Biggest Dividend Hikes Of The Past Week Aug 31 2013 
Weekly CFO Sells Highlight: ATRS, DENN, TTWO, JAH, ACET Jun 11 2013 
Aceto Corp. Reports Operating Results (10-Q) Feb 04 2011 
Aceto Corp. Reports Operating Results (10-Q) Nov 05 2010 
Aceto Corp. Reports Operating Results (10-Q) May 07 2010 

More From Other Websites
ETFs with exposure to Aceto Corp. : May 23, 2017 May 23 2017
Aceto Corp. :ACET-US: Earnings Analysis: Q3, 2017 By the Numbers : May 22, 2017 May 22 2017
Edited Transcript of ACET earnings conference call or presentation 5-May-17 1:00pm GMT May 09 2017
Aceto Corp. breached its 50 day moving average in a Bearish Manner : ACET-US : May 8, 2017 May 08 2017
Investor Network: Aceto Corporation to Host Earnings Call May 05 2017
Aceto posts 3Q profit May 04 2017
ACETO Reports Fiscal 2017 Third Quarter Results May 04 2017
ACETO Board of Directors Declares Quarterly Cash Dividend  May 04 2017
Aceto Corp. – Value Analysis (NASDAQ:ACET) : April 24, 2017 Apr 24 2017
Aceto Corp. breached its 50 day moving average in a Bullish Manner : ACET-US : April 21, 2017 Apr 21 2017
ACETO Corporation Schedules Third Quarter Fiscal 2017 Financial Results News Release and Conference... Apr 21 2017
Democrats found a way to speak Trump's language in pharma debate Apr 04 2017
Aceto Corp. : ACET-US: Dividend Analysis : March 10th, 2017 (record date) : By the numbers : April... Apr 03 2017
ACETO Subsidiary, Rising Pharmaceuticals, Launches Zileuton Extended Release Tablets, 600 mg Mar 31 2017
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg Mar 28 2017
Should You Get Rid of INC Research (INCR) Now? Mar 08 2017
Top Ranked Value Stocks to Buy for March 6th Mar 06 2017
Should You Get Rid of Ensign Group (ENSG) Now? Mar 03 2017
Top Ranked Value Stocks to Buy for February 28th Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)